Montelukast Tablet
Product Images NDC 68001-361

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Montelukast (NDC 68001-361). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Montelukast 30s

Montelukast Sodium Tablets, USP 10 mg oral tablets label showing the product name and strength prominently with instructions for pharmacists and storage conditions. The label indicates the product contains 30 tablets and is manufactured for BluePoint Laboratories by Macleods Pharmaceuticals Ltd., India. The label bears NDC 68001-361-04 and includes barcodes and a revision date of 08/2020.*

FDA Label Image

Montelukast 500s

Montelukast Sodium Tablets, USP 10 mg film-coated tablet label showing product name, strength, and form. The label indicates prescription use, storage instructions at 20° to 25°C with permitted excursions, and packaging information for 500 tablets. It lists BluePoint Laboratories as the labeler and Macleods Pharmaceuticals Ltd., India, as the manufacturer. Additional pharmacist and safety instructions are also included.*

FDA Label Image

Montelukast 90s

Montelukast Sodium Tablets USP 10 mg with 90 tablets per package. The label indicates this prescription oral tablet is for adults 15 years and older. Manufactured for BluePoint Laboratories and by Macleods Pharmaceuticals Ltd., India. Storage instructions and pharmacist dispensing guidance are included on the label.*

FDA Label Image

Montelukast-fig-1 (Montelukast Fig 1)

A line chart showing mean percent change from baseline over weeks in treatment for Placebo and Montelukast Sodium. The x-axis represents weeks in treatment from 0 to 15, including a washout period, and the y-axis shows mean percent change. Montelukast Sodium shows a higher increase compared to Placebo throughout the treatment period.*

FDA Label Image

Montelukast-structural (Montelukast Structural)

Chemical structure of Montelukast showing its molecular components including aromatic rings, sulfur, chlorine, and a carboxylate group with sodium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.